Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

导出 LinkOut

翻译打印收藏纠错

作者： Mark S,Freedman ^[1] ; Giancarlo,Comi ^[2] ; Nicola,De Stefano ^[3] ; Frederik,Barkhof ^[4] ; Chris H,Polman ^[4] ; Bernard M J,Uitdehaag ^[4] ; Lorenz,Lehr ^[5] ; Bettina,Stubinski ^[5] ; Ludwig,Kappos ^[6]

作者单位： Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada. Electronic address: mfreedman@toh.on.ca. ^[1] Department of Neurology and Institute of Experimental Neurology, Università Vita-Salute San Raffaele, Via Olgettina 60, 20132 Milan, Italy. ^[2] Department of Neurology, Neurosurgery & Behavioral Sciences, University of Siena, Viale Bracci 2, 53100 Siena, Italy. ^[3] VU University Medical Center, Postbus 7057, 1007 MB Amsterdam, The Netherlands. ^[4] Global Clinical Development Unit, Merck Serono S.A., 9 Chemin des Mines, 1202 Geneva, Switzerland. ^[5] Departments of Neurology and Biomedicine, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland. ^[6]

关键词 Clinically isolated syndrome Disease-modifying drug First clinical demyelinating event Glatiramer acetate Interferon beta Multiple sclerosis

DOI 10.1016/j.msard.2013.07.001

PMID 25878002

发布时间 2022-03-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交